

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2026

INTERIM RESULTS

The board (the “Board”) of directors (the “Directors”) of Yestar Healthcare Holdings Company Limited (the “Company”) is pleased to announce the unaudited interim results of the Company and its subsidiaries (collectively, the “Group”) for the six months ended 30 June 2026 (the “Period”) prepared in accordance with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and International Accounting Standard 34 *Interim Financial Reporting* (“IAS 34”) issued by the International Accounting Standards Board, together with the comparative figures for the corresponding period of 2025, as follows:

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2026

	Notes	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Revenue	4	661,614	802,634
Cost of sales		<u>(516,810)</u>	<u>(668,897)</u>
Gross profit		144,804	133,737
Other income and gains		3,213	8,880
Selling and distribution expenses		(37,309)	(38,802)
Administrative expenses		(75,381)	(77,683)
Reversal of impairment losses on financial assets, net		7,706	19,087
Other expenses		(22,414)	(17,552)
Finance costs		<u>(4,286)</u>	<u>(6,515)</u>
PROFIT BEFORE INCOME TAX	5	16,333	21,152
Income tax expense	6	<u>(16,812)</u>	<u>(10,004)</u>
(LOSS)/PROFIT FOR THE PERIOD		<u><u>(479)</u></u>	<u><u>11,148</u></u>
Attributable to:			
Owners of the Company		(3,168)	5,761
Non-controlling interests		<u>2,689</u>	<u>5,387</u>
		<u><u>(479)</u></u>	<u><u>11,148</u></u>
(LOSS)/EARNINGS PER SHARE			
ATTRIBUTABLE TO OWNERS OF THE COMPANY			
Basic and diluted (RMB cents)			
— For (loss)/profit for the period	8	<u><u>(0.14)</u></u>	<u><u>0.25</u></u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	2026 <i>RMB'000</i> (Unaudited)	2025 <i>RMB'000</i> (Unaudited)
(LOSS)/PROFIT FOR THE PERIOD	<u>(479)</u>	<u>11,148</u>
OTHER COMPREHENSIVE INCOME		
<i>Item that may be reclassified to profit or loss:</i>		
Exchange differences on translation of foreign operations	11,425	20,121
<i>Item that will not be reclassified to profit or loss:</i>		
Exchange differences on translation of the Company	<u>(6,294)</u>	<u>(16,018)</u>
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	<u>5,131</u>	<u>4,103</u>
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>4,652</u>	<u>15,251</u>
Attributable to:		
Owners of the Company	1,963	9,864
Non-controlling interests	<u>2,689</u>	<u>5,387</u>
	<u>4,652</u>	<u>15,251</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

		30 June 2026	31 December 2025
	Notes	RMB'000 (Unaudited)	RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		69,693	72,387
Right-of-use assets		26,474	27,466
Other intangible assets		80,227	87,262
Goodwill		55,869	55,869
Deposits paid for acquisition of property, plant and equipment		48,802	13,010
Deferred tax assets		15,226	14,933
Total non-current assets		296,291	270,927
CURRENT ASSETS			
Inventories		212,657	194,269
Trade and bills receivables	9	301,014	363,302
Prepayment and other receivables		121,185	131,328
Pledged deposits		47	47
Cash and cash equivalents		194,437	234,359
Total current assets		829,340	923,305
CURRENT LIABILITIES			
Bank and other borrowings	10	154,000	160,900
Trade payables	11	179,262	207,328
Contract liabilities		35,266	33,948
Other payables and accruals	12	158,655	194,960
Lease liabilities		10,878	12,337
Tax payable		76,113	66,126
Total current liabilities		614,174	675,599
NET CURRENT ASSETS		215,166	247,706

		30 June 2026	31 December 2025
	<i>Notes</i>	<i>RMB'000</i>	<i>RMB'000</i>
		(Unaudited)	(Audited)
NON-CURRENT LIABILITIES			
Bank and other borrowings	<i>10</i>	27,490	24,740
Lease liabilities		10,141	12,983
Deferred tax liabilities		41,799	44,065
Other payables	<i>12</i>	25,754	29,115
Total non-current liabilities		105,184	110,903
NET ASSETS		406,273	407,730
EQUITY			
Equity attributable to owners of the Company			
Share capital		46,576	46,576
Reserves		333,040	331,524
		379,616	378,100
Non-controlling interests		26,657	29,630
TOTAL EQUITY		406,273	407,730

NOTES

For the six months ended 30 June 2026

1. GENERAL

Yestar Healthcare Holdings Company Limited (the “Company”) was incorporated in the Cayman Islands on 1 February 2012 as an exempted company with limited liability under the Companies Act, Chapter 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The registered office address of the Company is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. In the opinion of the directors, the Company’s ultimate controlling shareholders are Jeane Hartono, Rico Hartono, James Hartono and Chen Chen Irene Hartono.

The Company’s shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) since 11 October 2013.

The Company is an investment holding company. During the six months ended 30 June 2026, the Company’s subsidiaries were involved in the following principal activities:

- manufacture and sale of color photographic paper, industrial NDT x-ray films and PWB films, and trading of imaging equipment; and
- manufacture and sale of medical dry films, medical wet films and dental films, and distribution of medical equipment and diagnostic reagents.

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP’S ACCOUNTING POLICIES

(a) Basis of preparation

The interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2025. This financial information is presented in Renminbi (“RMB”) and all values are rounded to the nearest thousand except when otherwise indicated.

(b) Application of new and amendments to IFRS Accounting Standards

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following revised IFRS Accounting Standards for the first time for the current period’s financial information.

Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards — Volume 11

The adoption of the above amendments to IFRS Accounting Standards in the current period has no material effect on the amounts reported and/or disclosures set out in these interim condensed consolidated financial statements.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has two reportable operating segments as follows:

- (a) Imaging printing products: manufacture and sale of color photographic paper, industrial NDT x-ray films and PWB films, and trading of imaging equipment; and
- (b) Medical products and equipment: manufacture and sale of medical dry films, medical wet films and dental films, and distribution of medical equipment and diagnostic reagents.

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on reportable segment profit/loss, which is a measure of adjusted profit/loss before income tax. The adjusted profit/loss before income tax is measured consistently with the Group's profit/loss before income tax except that corporate and unallocated expenses are excluded from this measurement.

Segment assets exclude unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

Intersegment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

The Group manufactures certain medical films, which are grouped under the medical products and equipment segment, in the factory under the imaging printing products segment. Accordingly, relevant expenses, assets and liabilities have been allocated to the respective segments on a reasonable and consistent basis for the segment reporting purpose.

The following tables present revenue and profit/loss information regarding the Group's operating segments for the six months ended 30 June 2026 and 2025:

Six months ended 30 June 2026

	Imaging printing products <i>RMB'000</i> (Unaudited)	Medical products and equipment <i>RMB'000</i> (Unaudited)		Total <i>RMB'000</i> (Unaudited)
Segment revenue				
Sales to external customers	<u>129,944</u>	<u>531,670</u>		<u>661,614</u>
Segment results	(1,034)	35,574		34,540
<i>Reconciliation:</i>				
Net corporate and other unallocated expenses				<u>(18,207)</u>
Profit before income tax				<u><u>16,333</u></u>
	Imaging printing products <i>RMB'000</i> (Unaudited)	Medical products and equipment <i>RMB'000</i> (Unaudited)	Corporate and unallocated <i>RMB'000</i> (Unaudited)	Total <i>RMB'000</i> (Unaudited)
Other segment information:				
Depreciation of property, plant and equipment	790	3,291	—	4,081
Depreciation of right-of-use assets	55	4,195	—	4,250
Amortisation of other intangible assets	25	7,170	—	7,195
Reversal of allowance for inventories	(2,171)	(1,443)	—	(3,614)
Reversal of impairment losses on financial assets, net	(1)	(4,205)	(3,500)	(7,706)
Impairment of property, plant and equipment	—	3,341	—	3,341
Impairment of right-of-use assets	—	1,059	—	1,059
Gain on disposal of property, plant and equipment	(127)	(158)	—	(285)
Capital expenditure*	822	4,066	—	4,888

* Capital expenditure consists of additions to property, plant and equipment and other intangible assets.

Six months ended 30 June 2025

	Imaging printing products <i>RMB'000</i> (Unaudited)	Medical products and equipment <i>RMB'000</i> (Unaudited)		Total <i>RMB'000</i> (Unaudited)
Segment revenue				
Sales to external customers	80,556	722,078		802,634
Segment results (<i>note</i>)	(10,817)	35,081		24,264
<i>Reconciliation:</i>				
Net corporate and other unallocated expenses				(3,112)
Profit before income tax				21,152
	Imaging printing products <i>RMB'000</i> (Unaudited)	Medical products and equipment <i>RMB'000</i> (Unaudited)	Corporate and unallocated <i>RMB'000</i> (Unaudited)	Total <i>RMB'000</i> (Unaudited)
Other segment information:				
Depreciation of property, plant and equipment	4,862	586	—	5,448
Depreciation of right-of-use assets	327	6,131	—	6,458
Amortisation of other intangible assets	32	7,302	—	7,334
Reversal of allowance for inventories	(197)	(3,743)	—	(3,940)
Reversal of impairment losses on financial assets, net (<i>note</i>)	(4)	(17,439)	(1,644)	(19,087)
Impairment of property, plant and equipment	—	1,385	—	1,385
Impairment of right-of-use assets	1,617	6,742	—	8,359
Gain on disposal of property, plant and equipment	(37)	(61)	—	(98)
Capital expenditure*	6	1,037	—	1,043

* Capital expenditure consists of additions to property, plant and equipment and other intangible assets.

Note:

Having considered the nature of the loans provided to a business partner is for business development of the Group, the management considered that it is more appropriate to classify such assets as corporate assets rather than as segment assets under the imaging printing products segment as was the case in the previous years. To conform to current period's presentation, segment loss of imaging printing products segment for the six months ended 30 June 2025 increased from RMB9,173,000 to RMB10,817,000 whereas corporate expense for the six months ended 30 June 2025 decreased by the same extent to RMB3,112,000, which is resulted from reclassifying reversal of impairment loss for such loan receivables amounting to RMB1,644,000 as corporate income.

The following table presents the asset and liability information of the Group's operating segments as at 30 June 2026 and 31 December 2025:

As at 30 June 2026

	Imaging printing products RMB'000 (Unaudited)	Medical products and equipment RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
Segment assets	145,851	905,885	1,051,736
<i>Reconciliation:</i>			
Corporate and other unallocated assets			<u>73,895</u>
Total assets			<u>1,125,631</u>
Segment liabilities	80,593	614,978	695,571
<i>Reconciliation:</i>			
Corporate and other unallocated liabilities			<u>23,787</u>
Total liabilities			<u>719,358</u>

As at 31 December 2025

	Imaging printing products RMB'000 (Audited)	Medical products and equipment RMB'000 (Audited)	Total RMB'000 (Audited)
Segment assets	139,625	987,663	1,127,288
<i>Reconciliation:</i>			
Corporate and other unallocated assets			<u>66,944</u>
Total assets			<u>1,194,232</u>
Segment liabilities	93,575	669,097	762,672
<i>Reconciliation:</i>			
Corporate and other unallocated liabilities			<u>23,830</u>
Total liabilities			<u>786,502</u>

Information about major customers

During the six months ended 30 June 2026, the Group had one individual customer from whom the revenue derived by selling medical imaging products and imaging printing products of RMB111,213,000 (six months ended 30 June 2025: RMB113,083,000) accounted for approximately 16.81% (six months ended 30 June 2025: approximately 14.09%) of the Group's total revenue during the six months ended 30 June 2026.

Geographical information

Since the Group solely operates business in Mainland China and all of the non-current assets of the Group are located in Mainland China, geographical information required by IFRS 8 Operating Segments is not presented.

Seasonality of operations

The Group's operations are not subject to seasonality.

4. REVENUE

An analysis of revenue is as follows:

	For the six months ended	
	30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Revenue from contracts with customers	<u>661,614</u>	<u>802,634</u>

Disaggregated revenue information for revenue from contracts with customers

For the six months ended 30 June 2026

Segments	Imaging printing products <i>RMB'000</i> (Unaudited)	Medical products and equipment <i>RMB'000</i> (Unaudited)	Total <i>RMB'000</i> (Unaudited)
Types of goods or services			
Sale of goods	128,758	521,495	650,253
Rendering of services	1,186	10,175	11,361
Total revenue from contracts with customers	<u>129,944</u>	<u>531,670</u>	<u>661,614</u>
Timing of revenue recognition			
Goods transferred at a point in time	128,758	521,495	650,253
Services transferred over time	1,186	10,175	11,361
Total revenue from contracts with customers	<u>129,944</u>	<u>531,670</u>	<u>661,614</u>

For the six months ended 30 June 2025

Segments	Imaging printing products <i>RMB'000</i> (Unaudited)	Medical products and equipment <i>RMB'000</i> (Unaudited)	Total <i>RMB'000</i> (Unaudited)
Types of goods or services			
Sale of goods	79,813	701,880	781,693
Rendering of services	743	20,198	20,941
Total revenue from contracts with customers	<u>80,556</u>	<u>722,078</u>	<u>802,634</u>
Timing of revenue recognition			
Goods transferred at a point in time	79,813	701,880	781,693
Services transferred over time	743	20,198	20,941
Total revenue from contracts with customers	<u>80,556</u>	<u>722,078</u>	<u>802,634</u>

5. PROFIT BEFORE INCOME TAX

The Group's profit before income tax is arrived at after charging/(crediting):

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Cost of inventories sold and services provided	516,810	668,897
Depreciation of property, plant and equipment	4,081	5,448
Depreciation of right-of-use assets	4,250	6,458
Amortisation of other intangible assets	7,195	7,334
Impairment of non-financial assets		
— Property, plant and equipment	3,341	1,385
— Right-of-use assets	1,059	8,359
	<u>4,400</u>	<u>9,744</u>
Lease payments not included in the measurement of lease liabilities	3,253	10,029
Employee benefit expense including		
— Wages and salaries	49,052	67,231
— Pension scheme contributions	4,595	6,117
	<u>53,647</u>	<u>73,348</u>
Exchange differences, net	11,005	4,221
Gain on disposal of property, plant and equipment	(285)	(98)
	<u><u>(285)</u></u>	<u><u>(98)</u></u>

6. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands ("BVI"), the Group is not subject to any income tax in the Cayman Islands and BVI.

Hong Kong profits tax is to be provided at the rate of 16.5% on the estimated assessable profits arising in Hong Kong. No provision for Hong Kong profits tax has been made as the Group had no assessable profits derived from or earned in Hong Kong during the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

The provision for current income tax in Mainland China is based on the statutory rate of 25% of the assessable profits of the Group as determined in accordance with the PRC Corporation Income Tax Law which was approved and became effective on 1 January 2008.

Yestar (Guangxi) Medical System Co., Ltd. (“Yestar Medical”) and Yestar (Guangxi) Imaging Technology Co., Ltd. (“Yestar Imaging”) were accredited as a high and new technology enterprise (“HNTE”) for the six months ended 30 June 2026 and 2025. The HNTE certificate needs to be renewed every three years so as to enable Yestar Medical and Yestar Imaging to enjoy the preferential rate of 15%.

The major components of income tax charge for the period were as follows:

	For the six months ended	
	30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Current tax		
— PRC charge for the period	19,371	10,472
Deferred tax	(2,559)	(468)
Income tax expense	16,812	10,004

7. DIVIDENDS

The directors did not recommend the payment of an interim dividend in respect of the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

The shareholders did not declare any dividend for the year ended 31 December 2025 at the annual general meeting of the Company on 29 May 2026.

8. (LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY

The calculation of basic (loss)/earnings per share amount is based on the (loss)/profit for the period attributable to owners of the Company, and the weighted average number of ordinary shares in issue during the six months ended 30 June 2026 and 2025.

The calculation of basic (loss)/earnings per share is based on:

	For the six months ended	
	30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
(Loss)/profit		
(Loss)/profit attributable to owners of the Company, used in the basic (loss)/earnings per share calculation	(3,168)	5,761
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic (loss)/earnings per share calculation (thousands)	2,331,590	2,331,590

The diluted (loss)/earnings per share are the same as the basic (loss)/earnings per share for the six months ended 30 June 2026 and 2025, as there were no dilutive potential ordinary shares in existence during the period or in prior period.

9. TRADE AND BILLS RECEIVABLES

	30 June 2026 <i>RMB'000</i> (Unaudited)	31 December 2025 <i>RMB'000</i> (Audited)
Trade receivables	330,939	387,835
Bills receivables	20,627	28,225
Impairment provision	(50,552)	(52,758)
	<u>301,014</u>	<u>363,302</u>

An aging analysis of trade receivables at the end of the reporting period, based on the invoice date and net of provisions, is as follows:

	30 June 2026 <i>RMB'000</i> (Unaudited)	31 December 2025 <i>RMB'000</i> (Audited)
Within 90 days	144,942	181,014
91 to 180 days	88,681	95,758
181 to 365 days	23,583	17,524
1 to 2 years	15,895	30,802
Over 2 years	7,286	9,979
	<u>280,387</u>	<u>335,077</u>

10. BANK AND OTHER BORROWINGS

	30 June 2026 <i>RMB'000</i> (Unaudited)	31 December 2025 <i>RMB'000</i> (Audited)
Bank and other loans	<u>181,490</u>	<u>185,640</u>
Analysed as:		
Secured and/or guaranteed (<i>note</i>)	153,860	155,000
Unsecured	<u>27,630</u>	<u>30,640</u>
	<u>181,490</u>	<u>185,640</u>
Analysed as:		
Current	154,000	160,900
Non-current	<u>27,490</u>	<u>24,740</u>
	<u>181,490</u>	<u>185,640</u>

Note:

As at 30 June 2026, the Group's bank loans of RMB64,950,000 (31 December 2025: RMB75,000,000) were secured by the pledge of the Group's buildings with a carrying amount of approximately RMB63,428,000 (31 December 2025: RMB66,147,000). Other loans of RMB88,910,000 (31 December 2025: RMB80,000,000) were guaranteed by certain of the Company's subsidiaries, independent third parties, a non-controlling shareholder and/or directors of subsidiaries.

11. TRADE PAYABLES

An aging analysis of the outstanding trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	30 June 2026 <i>RMB'000</i> (Unaudited)	31 December 2025 <i>RMB'000</i> (Audited)
Within 90 days	172,516	200,167
91 to 180 days	398	178
181 to 365 days	148	268
1 to 2 years	3	2,894
Over 2 years	6,197	3,821
	179,262	207,328

12. OTHER PAYABLES AND ACCRUALS

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Current portion:		
Other payables	30,238	38,984
Value added tax payable	37,122	39,277
Payroll and welfare payable	6,932	11,123
Interest payable	237	218
Payables to non-controlling interests (<i>notes</i>)	84,126	105,358
	158,655	194,960
Non-current portion:		
Payables to non-controlling interests (<i>notes</i>)	19,282	22,549
Deferred government grant	6,472	6,566
	25,754	29,115
	184,409	224,075

Notes:

As at 30 June 2026, payables to non-controlling interests mainly represent the contractual obligations of the Group to acquire the remaining 5.7% (31 December 2025: 17.8%) and 30% (31 December 2025: 30%) interests in Shengshiyuan and Kaihongda respectively.

The details of the arrangement relating to the acquisition of the remaining interests in each of Shengshiyuan and Kaihongda are as follows:

- a) Pursuant to the share purchase agreement entered into between Yestar Medical, Ms. Liu Yanling, Ms. Li Xu, Mr. Ai Jiaying, Mr. Zhang Lixiong and Mr. Li Shenlian on 11 November 2016, Yestar Medical acquired the 70% equity interest in Shengshiyuan. Yestar Medical is obligated to acquire the remaining 30% equity interest in Shengshiyuan if the respective net profits of Shengshiyuan in 2017, 2018 and 2019 have reached the annual guarantee profits. The maximum consideration shall not exceed RMB120 million. Since Shengshiyuan has met the annual guarantee profit targets for the years from 2017 to 2019, Yestar Medical was negotiating with shareholders of the remaining 30% equity interest of Shengshiyuan to purchase their interest.

In 2024, Yestar Medical entered into a separate share transfer agreement with the aforementioned shareholders of Shengshiyuan to acquire the remaining 30% equity interest in Shengshiyuan for a total consideration of RMB99,266,000. As at 30 June 2026, the Group has cumulatively paid the consideration of RMB82,638,000 (31 December 2025: RMB63,462,000) to the aforementioned shareholders. During the six months ended 30 June 2026, the Group completed the acquisition of an additional 12.1% (31 December 2025: 12.2%) equity interest in Shengshiyuan. Accordingly, the corresponding put option reserve of RMB38,503,000, relating to the additional 12.1% equity interest acquired during the period, was transferred to other reserve in the interim condensed consolidated statement of changes in equity accordingly.

As at 30 June 2026, the Group recognised the consideration payable of RMB15,929,000 (31 December 2025: RMB34,673,000) and the dividend payable to the above shareholders of Shengshiyuan of RMB14,699,000 (31 December 2025: RMB22,200,000) as payables to non-controlling interests. Since the payables to non-controlling interests have been agreed to be settled in 3 phases by 30 September 2027, amounts of RMB11,346,000 (31 December 2025: RMB34,324,000) and RMB19,282,000 (31 December 2025: RMB22,549,000) were classified as current liabilities and non-current liabilities respectively as at 30 June 2026.

- b) Pursuant to the share purchase agreement entered into between Yestar Medical, Mr. Pang Haibin, Mr. Xie Dingjie, Ms. An Hong, Mr. Yu Huimin and Mr. Zhu Yongping on 20 September 2017, Yestar Medical acquired the 70% equity interest in Kaihongda. Yestar Medical is obligated to acquire the remaining 30% equity interest in Kaihongda if the respective net profits of Kaihongda in 2017, 2018 and 2019 have reached the annual guarantee profits. The maximum consideration shall not exceed RMB71.28 million. Since Kaihongda has met the annual guarantee profit targets for the years from 2017 to 2019, Yestar Medical was negotiating with shareholders of the remaining 30% equity interest of Kaihongda to purchase their equity interest. No agreement was reached as at the date of this announcement.

As at 30 June 2026, the Group recognised the consideration payable of RMB65,336,000 (31 December 2025: RMB65,336,000) and dividend payable to the above shareholders of Kaihongda of RMB7,444,000 (31 December 2025: RMB5,698,000) as payables to non-controlling interests under current liabilities.

MANAGEMENT DISCUSSION AND ANALYSIS

ABOUT YESTAR

Yestar Healthcare Holdings Company Limited (“Yestar” or the “Company”, together with its subsidiaries, the “Group”) is among the largest distributors and service providers of in vitro diagnostic products in the People’s Republic of China (the “PRC”). The Group primarily engages in the distribution of IVD products in Beijing, Guangzhou, Shenzhen, and the provinces of Anhui, Fujian, Guangdong, Guangxi, Hainan, Hunan, Jiangsu and Hebei, as well as the Inner Mongolia autonomous region. The Group also manufactures medical films for X-Ray, magnetic resonance imaging (MRI), and computer tomography scan (CT scan) etc. for Fujifilm in the PRC, and manufactures, markets and sells dental film and medical dry film products under its “Yes!Star” brand.

MARKET OVERVIEW

In-vitro diagnostics (IVD) serve as a cornerstone of modern healthcare systems, providing critical data support for disease prevention, diagnosis, and treatment by analysing biological samples such as blood and bodily fluids. As healthcare standards and public health awareness improve in the PRC, the IVD industry has shifted from rapid expansion to a period of significant adjustment. According to the *Annual Report on China’s In-Vitro Diagnostics Industry (2025 Edition)* jointly published by the Medical Laboratory Industry Division of the National Association of Health Industry and Enterprise Management and other institutions, the size of the PRC IVD market reached approximately RMB108 billion in 2025, representing a year-on-year (“yoy”) decrease of about 10% from RMB120 billion in 2024. Including exports, raw materials, accessories, and consumables, the total industry size was approximately RMB160 billion, down approximately 6% yoy. This slowdown was mainly due to the expanded implementation of volume-based procurement (“VBP”), the unbundling of testing packages, and the widespread adoption of DRG/DIP payment systems, which have pressured both testing demand and pricing in hospitals. Nevertheless, factors such as an aging population, increased demand for chronic disease and cancer screening, and ongoing investment in primary healthcare continue to drive long-term industry growth. The report forecasts the market will rebound to around RMB140 billion by 2030, representing a compound annual growth rate (“CAGR”) of about 5% over the next five years.

BUSINESS OVERVIEW

Advanced Materials Industry

During the Period, the Company was preparing its production and manufacturing in the advanced materials industry, and invest in the enhanced research and development equipment. On 6 February 2026, the Company had entered into an agreement for the acquisition of the various advanced materials equipment for a total consideration of US\$5,350,000 for the purpose of leading the Company to become one of the self-sufficient advanced materials engineers and manufacturers. Those acquired equipment constitute the essential research and development equipment and comprehensive coating production line that enables the Group to conduct research, testing, evaluation and ultimately produce and manufacture advanced membrane materials. The Board believes that leveraging the Group's experience in refined production of the S2 film camera in the past 2 years, the acquisitions would diversify the Group's business segment through synergy effect on materials research and development.

For details, please refer to the announcement of the Company dated 6 February and 13 March 2026.

Research and Development and Production of Proprietary Brand Film Cameras

The research and development ("R&D") work for the Group's proprietary brand "Yes!Star" S2 film camera has completed functional and performance verification and testing. Preparations for production commencement are progressing in an orderly manner. It is believed that the product will be officially launched in the near future and is expected to become a new performance growth driver for the Group going forward. The Group will continue to step up its investment in R&D, accelerate technological advancement and innovation, and further enhance its core competitiveness, thereby injecting strong momentum into the long-term growth of the Group.

RESULTS OVERVIEW

The Group's overall revenue decreased by approximately 17.6% yoy to RMB661.6 million (six months ended 30 June 2025: RMB802.6 million). Gross profit increased by approximately 8.3% yoy to RMB144.8 million (six months ended 30 June 2025: RMB133.7 million). The decrease in revenue was mainly due to the fact that the medical segment, being the Group's main source of income, was impacted by the centralised procurement policy in the PRC.

Selling and distribution expenses decreased by approximately 3.8% yoy to RMB37.3 million (six months ended 30 June 2025: RMB38.8 million), due to the decrease in staff costs as a result of reduction in the number of sales personnel.

Administrative expenses decreased by approximately 3.0% yoy to RMB75.4 million (six months ended 30 June 2025: RMB77.7 million), mainly due to strengthened internal control measures to avoid unnecessary expenses.

Finance costs decreased by approximately 34.2% yoy to RMB4.3 million (six months ended 30 June 2025: RMB6.5 million), due to reduction of bank borrowings.

Other expenses increased significantly by approximately 27.7% yoy to RMB22.4 million (six months ended 30 June 2025: RMB17.6 million), which was principally the result of exchange rate fluctuations.

Other income dropped by approximately 63.8% yoy to RMB3.2 million (six months ended 30 June 2025: RMB8.9 million), which was mainly due to the reduction of government subsidy.

Basic loss per share attributable to the owners of the Company amounted to RMB0.14 cents (six months ended 30 June 2025: basic earnings per share of RMB0.25 cents). The Board has resolved not to declare any interim dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

Medical Business — 80.4% of Overall Revenue

During the Period, the Group noted a decline in the demand for IVD consumables, which was mainly attributable to policies such as the national healthcare insurance reform and the centralised procurement. Segment revenue was RMB531.7 million (six months ended 30 June 2025: RMB722.1 million), representing a yoy decrease of approximately 26.4%. However, the gross profit margin of this segment increased by 5.8 percentage points (“p.p.”) to approximately 22.7% (six months ended 30 June 2025: approximately 16.9%), which was due to the implementation of effective selling strategies of the Group by terminating customers with low profit margin.

Non-medical Business — 19.6% of Overall Revenue

Apart from the medical business segment, the Group’s non-medical business mainly consists of the manufacturing, marketing, distribution and sale of Fujifilm colour photographic paper (professional and minilab), as well as industrial imaging products (NDT x-ray films and PWB films) in the PRC. The Group also manufactures, markets and sells NDT x-ray film under the house brand “Yes!Star”. The demand for this segment increased during the Period and generated relatively stable cash flow for the Group. Revenue from the non-medical business for the Period was RMB129.9 million (six months ended 30 June 2025: RMB80.6 million), representing a yoy increase of approximately 61.3%. The quantity and price of industrial film have both increased, as the demand for industrial film has rebounded and global silver prices have risen, resulting in a significant increase in the cost of industrial film. The gross profit margin of this segment increased by 4.3 p.p. to 18.5%, which was mainly attributable to the shift of all increased cost of industrial film to customers during the Period.

OUTLOOK

The current growth rate of the PRC IVD industry has moderated compared to previous market expectations. While the industry faces near-term pressure, its long-term growth fundamentals remain intact, and it is expected to resume a moderate growth trajectory over the next five years. According to the analysis in the Annual Report on China's In-Vitro Diagnostics Industry (2025 Edition) by the National Association of Health Industry and Enterprise Management, the CAGR of the PRC IVD market from 2024 to 2029 is expected to remain at around 5%, with the market size projected to approach RMB140 billion by 2029. The moderation in growth is primarily attributable to the implementation of national policies such as the expansion of VBP for medical consumables, the reform of DRG/DIP payment methods, and price reductions from the unbundling of testing packages. Nevertheless, long-term drivers remain robust: the deepening population aging, the release of demand for chronic disease management, and the growing awareness of early diagnosis and screening will continue to expand market potential. Under policy guidance, compliant high-value-added sectors such as molecular diagnostics and home-based testing are poised to present structural growth opportunities.

Despite strong long-term prospects, the industry continues to face clear short-term challenges. The normalisation of VBP has raised barriers to hospital access, and product homogenisation has increased price competition, putting short-term pressure on overall industry profitability. Yestar's development has always been closely aligned with industry cycles. While proactively addressing the challenges arising from the current market adjustment, Yestar remains focused on capturing long-term growth opportunities. Looking ahead, the PRC IVD industry will steadily recover under the combined impetus of supportive regulatory policies and technological innovation. Yestar will proactively adapt to VBP rules, increase investment in differentiated R&D, pursue breakthroughs during this period of pressure, and collaborate with industry partners to promote high-quality sector development, providing stronger support for national healthcare.

FINANCIAL REVIEW

Liquidity and Financial Resources

During the Period, the Group finances its daily operation through a combination of net internally generated funds from operation and borrowings. As at 30 June 2026, the Group had cash and cash equivalents of approximately RMB194.4 million (31 December 2025: approximately RMB234.4 million). The decrease in cash and cash equivalents was due to advance payment for the purchase of large equipment and intangible assets.

The total current bank and other borrowings of the Group as at 30 June 2026 was approximately RMB154.0 million (31 December 2025: approximately RMB160.9 million). As at 30 June 2026, all borrowings of the Group are denominated in Renminbi ("RMB"), which is the presentation currency of the Group.

Current Ratio

As at 30 June 2026, the Group's current ratio was approximately 1.35 (31 December 2025: approximately 1.37), which was calculated based on the total current assets of approximately RMB829.3 million and the total current liabilities of approximately RMB614.2 million.

Gearing Ratio

As at 30 June 2026, no gearing ratio was presented as the Group was in a net cash position (31 December 2025: Nil), which was calculated as the net debt which includes the bank and other borrowings less cash and cash equivalents divided by equity attributable to owners of the Company plus net debt at the end of 30 June 2026.

Selling and Distribution Expenses

The Group's selling and distribution expenses decreased by approximately 3.8% from approximately RMB38.8 million for the six months ended 30 June 2025 to approximately RMB37.3 million for the Period, and accounted for approximately 4.8% and 5.6%, respectively, of the Group's revenue for the respective reporting periods. Such decrease in selling and distribution expenses was mainly due to strengthen internal control to avoid unnecessary expense.

Administrative Expenses

The Group's administrative expenses decreased by approximately 3.0% from approximately RMB77.7 million for the six months ended 30 June 2025 to approximately RMB75.4 million for the Period, and accounted for approximately 9.7% and approximately 11.4%, respectively, of the Group's revenue for the respective reporting periods. Such decrease in administrative expenses was due to the strict measures of the Group to optimise its cost management to reduce unnecessary operating expenses as well as the reduction of staff.

Finance Costs

The Group's finance costs consisted mainly of interest expenses on bank and other borrowings. The aggregate amount of interest incurred during the Period was approximately RMB4.3 million (six months ended 30 June 2025: approximately RMB6.5 million). Such decrease was mainly due to reduction of bank borrowings. During the Period, interest rates of the interest-bearing loans ranged from 1.95% to 4.80%, while those for the six months ended 30 June 2025 ranged from 1.80% to 6.90%.

Foreign Exchange Exposure

Most of the revenue-generating operations of the Group conducted their transactions in RMB, which is the presentation currency of the Group.

During the Period, the Group was exposed to minimal foreign exchange risk arising from the purchase of US dollars, and did not enter into any agreement to hedge its currency exposure. The Group will continue to closely monitor its foreign exchange exposure in order to minimise the foreign exchange risk.

Share Capital and Capital Structure

During the Period, there has been no change to the shares in issue and capital structure of the Company. The capital of the Company comprises ordinary shares and capital reserve.

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for equity shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Group finances its working capital requirements through a combination of funds generated from operations and bank borrowings.

Employees and Remuneration Policies

As at 30 June 2026, the Group had a total of 400 employees (six months ended 30 June 2025: 479 employees), including the Directors. The total staff costs (including the Directors' emoluments) for the Period were approximately RMB53.6 million (six months ended 30 June 2025: RMB73.3 million).

The remuneration policy of the Group is to ensure the fairness and competitiveness of total remuneration. The emoluments of executive Directors are determined based on the skills, knowledge, individual performance as well as contributions, the scope of responsibility and accountability of such Directors, taking into consideration the Company's performance and prevailing market conditions. The remuneration policy of independent non-executive Directors is to ensure that they are adequately compensated for their efforts and time dedicated to the Company's affairs including their participation in respective Board committees. Their emoluments are determined with reference to their skills, experience, knowledge, duties and market trends.

On top of basic salaries, bonuses may be paid by reference to the Group's performance as well as individual's performance. Other staff benefits include provision of welfare schemes covering pension insurance, unemployment insurance, maternity insurance, injury insurance, medical insurance, and central pension scheme.

Since the contribution to the pension schemes and for the Period, there was no contributions forfeited by the Group (31 December 2025: Nil) on behalf of its employees who leave the plan prior to vesting fully in such contribution, nor had there been any utilization of such forfeited contributions to reduce future contributions.

As at 30 June 2026, no forfeited contributions were available for utilization by the Group to reduce the existing level of contributions as described in paragraph 26(2) of Appendix D2 to the Listing Rules.

Significant Investments Held

The Group holds two one-year fixed-interest (annual interest rate: 6%) investment products from a company with the principal amount of US\$3.7 million and US\$4.4 million since 2022, which were expired on 31 May 2023 and 4 July 2023, respectively without renewal by the Group upon expiry.

The Group then agreed on the repayment plan with that company for the outstanding principal and interest relating to the above two investment products.

As at 30 June 2026, that company has settled a total of US\$5.0 million (31 December 2025: US\$5.0 million). The Company will keep a close monitor on collecting the outstanding receivable.

Save as disclosed above and except for investment in subsidiaries and associate during the Period, the Group did not hold any significant investment in equity interest in any other company.

Reversal of Financial Assets Impairment Loss under Expected Credit Loss Model

Financial assets impairment losses of RMB7.7 million under expected credit loss methodology was reversed for the Period (six months ended 30 June 2025: RMB19.1 million). The reversal was mainly due to the decrease in provision for impairment of trade receivables and the settlement of short-term loans from business parties during the Period.

Securities Investments

The Group did not have any securities investment in any investee company with a value of 5% or more of the total assets of the Group as at 30 June 2026, which is required to be disclosed under the Listing Rules.

Future Plans for Material Investments and Capital Assets

The Group did not have any other plans for material investments and capital assets as at 30 June 2026.

Material Acquisitions and Disposals of Subsidiaries and Affiliated Companies

The Group did not have any material acquisitions and other disposals of subsidiaries and affiliated companies during the Period.

Guarantee Performance in relation to the Acquisitions

The Group did not enter into any acquisition, which is required to be disclosed under the Listing Rules, that the party in contract required to commit or guarantee on the financial performance in any kinds for the Period.

Charge of Assets

As at 30 June 2026, certain of the Group's buildings with a net carrying amount of approximately RMB63,428,000 (31 December 2025: RMB66,147,000) were pledged to secure bank loans granted to the Group.

The Group's other loans of RMB88,910,000 (31 December 2025: RMB80,000,000) were guaranteed by certain of the Company's subsidiaries, independent third parties, a non-controlling shareholder and/or directors of subsidiaries.

Contingent Liabilities

The Group had no material contingent liabilities as at 30 June 2026.

Material Adverse Changes

Save as disclosed in this announcement, the Directors are not aware of any material adverse changes in the Group's financial or trading position since 30 June 2026.

OTHER INFORMATION

On 26 June 2026, the shareholders of Guangzhou Shengshiyuan Trading Co., Ltd. (廣州市盛仕源貿易有限公司) ("Shengshiyuan", an indirect non wholly-owned subsidiary of the Company) passed a written resolution to dissolve and deregister Shengshiyuan ("Voluntary Liquidation").

The Voluntary Liquidation was published and announced on the Enterprise Credit Information Publicity System (Guangdong) on 2 July 2026.

For details, please refer to the announcement of the Company dated 3 July 2026.

EVENT AFTER REPORTING PERIOD

Save as disclosed in this interim results announcement, there is no material subsequent event undertaken by the Company or by the Group after 30 June 2026 and up to the date of this announcement.

INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the Period (six months ended 30 June 2025: Nil).

COMPETITION AND CONFLICT OF INTERESTS

Save as disclosed above and except for the interests in the Group, none of the Directors, the controlling shareholders or substantial shareholders of the Company or any of their respective associates has engaged in any business that competes or may compete with the business of the Group or has any other conflict of interests with the Group during the Period.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES INCLUDING TREASURY SHARES

During the Period, neither the Company nor its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares (as defined under the Listing Rules)). As of 30 June 2026, there were no treasury shares (as defined under the Listing Rules) held by the Company.

CODE OF CONDUCT FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") contained in Appendix C3 to the Listing Rules as its own code of conduct for dealing in securities of the Company by the Directors.

Specific enquiries have been made with all Directors, who have confirmed in writing that they have complied with the required standard set out in the Model Code regarding their securities transactions for the Period.

The Board has also adopted the Model Code to regulate all dealings by relevant employees who are likely to be in possession of unpublished inside information of the Company in respect of securities in the Company under the CG Code. No incident of non-compliance with the Model Code by the Company's relevant employees has been noted during the Period after making reasonable enquiry.

CORPORATE GOVERNANCE PRACTICES

The Board believes that good corporate governance is one of the areas leading to the success of the Company and balancing the interests of shareholders, customers and employees, and the Board is devoted to ongoing enhancement of the efficiency and effectiveness of such principles and practices.

During the Period, the Board consider that the Company has complied with all the corporate governance codes (the "CG Code") as set out in Appendix C1 to the Listing Rules.

AUDIT COMMITTEE

The Company established an audit committee on 18 September 2013 with written terms of reference. The latest written terms of reference of audit committee in compliance with the Listing Rules are available on the websites of the Company and the Stock Exchange.

The responsibility of the audit committee is to assist the Board in fulfilling its audit duties through the review and supervision of the Company's financial reporting system, risk management and internal control systems, and to provide advice and comments to the Board. The members meet regularly with the external auditor and/or the Company's senior management for the review, supervision and discussion of the Company's financial reporting, risk management and internal control systems and ensure that the management has discharged its duty to have an effective risk management and internal control systems.

The audit committee comprises three independent non-executive Directors, Mr. Zhao Ziwei (Chairman of the audit committee), Mr. Zeng Jinsong and Mr. Koeswondo Michael David.

The interim results of the Group for the Period are unaudited but have been reviewed by the audit committee of the Company, which is of the opinion that the preparation of the interim financial information of the Group complied with the applicable accounting principles and standard, practices adopted by the Group, the Stock Exchange and legal requirements, and that adequate disclosures have been made.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

The Company's interim results announcement for the six months ended 30 June 2026 is published on the website of the Stock Exchange at <http://www.hkexnews.hk> and the Company's website at <http://www.yestarcorp.com>.

The interim report of the Company for the six months ended 30 June 2026 containing the information required by Appendix D2 to the Listing Rules will be dispatched to the shareholders of the Company who wish to receive a printed copy of the corporate communication in due course, and the same will also be published on the above websites in due course.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Wang Chunlai
CEO and executive Director

28 August 2026

As at the date of this announcement, the executive Directors are Mr. Wang Chunlai, Mr. Qiao Jinrong and Ms. Liao Changxiang; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.